P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib.

Abstract

The P16 (CDKN2Aink4a) gene is an endogenous CDK4/6 inhibitor. Palbociclib (PD0332991) is an anti-CDK4/6 chemical for cancer treatment. P16 is most frequently inactivated by copy number deletion and DNA methylation in cancers. It is well known that cancer cells with P16 deletion are more sensitive to palbociclib than those without. However, whether P16 methylation is related to palbociclib sensitivity is not known. By analyzing public pharmacogenomic datasets, we found that the IC50 of palbociclib in cancer cell lines (n = 522) was positively correlated with both the P16 expression level and P16 gene copy number. Our experimental results further showed that cancer cell lines with P16 methylation were more sensitive to palbociclib than those without. To determine whether P16 methylation directly increased the sensitivity of cancer cells to palbociclib, we induced P16 methylation in the lung cancer cell lines H661 and HCC827 and the gastric cancer cell line BGC823 via an engineered P16-specific DNA methyltransferase (P16-Dnmt) and found that the sensitivity of these cells to palbociclib was significantly increased. The survival rate of P16-Dnmt cells was significantly lower than that of vector control cells 48 hrs post treatment with palbociclib (10 μM). Notably, palbociclib treatment also selectively inhibited the proliferation of the P16-methylated subpopulation of P16-Dnmt cells, further indicating that P16 methylation can increase the sensitivity of cells to this CDK4/6 inhibitor. These results were confirmed in an animal experiment. In conclusion, inactivation of the P16 gene by DNA methylation can increase the sensitivity of cancer cells to palbociclib.

• Authors: Paiyun Li, Xuehong Zhang, Liankun Gu, Jing Zhou, Dajun Deng
• Journal: PloS one (PLoS One) Vol. 14 Issue 10 Pg. e0223084 ( 2019) ISSN: 1932-6203 [Electronic] United States
• PMID: 31652270 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cyclin-Dependent Kinase Inhibitor p16
• Piperazines
• Pyridines
• DNA Modification Methylases
• CDK4 protein, human
• CDK6 protein, human
• Cyclin-Dependent Kinase 4
• Cyclin-Dependent Kinase 6
• palbociclib

Topics

• Cell Line, Tumor
• Cell Proliferation (drug effects)
• Cyclin-Dependent Kinase 4 (antagonists & inhibitors, genetics)
• Cyclin-Dependent Kinase 6 (antagonists & inhibitors, genetics)
• Cyclin-Dependent Kinase Inhibitor p16 (genetics)
• DNA Methylation (drug effects)
• DNA Modification Methylases (genetics)
• Drug Resistance, Neoplasm (genetics)
• Gene Dosage (genetics)
• Gene Expression Regulation, Neoplastic (drug effects)
• Humans
• Lung Neoplasms (drug therapy, genetics)
• Piperazines (pharmacology)
• Pyridines (pharmacology)
• Stomach Neoplasms (drug therapy, genetics, pathology)